Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad 500 082, India.
Neurol India. 2010 May-Jun;58(3):403-6. doi: 10.4103/0028-3886.66085.
Despite the increasing use of recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke, uncertainty persists about the short- and long-term outcome of the thrombolysed patients.
To identify predictors of major neurological improvement at 24 h after intravenous rt-PA administration in patients of acute ischemic stroke and their relationship with outcome at 12 months.
We analyzed the data of the patients with acute ischemic stroke treated as per the National Institute of Neurological Disorders and Stroke (NINDS) criteria with intravenous rt-PA between January 2000 and June 2009 at a tertiary care center in south India. Major neurological improvement was defined by an 8-point improvement in National Institute of Health Stroke Scale (NIHSS) score or an NIHSS score of 0 or 1 at 24 h. Good outcome was defined as a 12-month modified Rankin Scale (mRS) of 0 to 1.
Of the 72 patients with acute ischemic stroke treated with intravenous rt-PA, 23 (32%) patients had major neurological improvement at 24 h. Age <60 years (OR 1.9, 95% CI 1.7 to 3.2), admission glucose levels <8 mmol/L (OR 3.87, 95% CI 1.9 to 9.2) and mild to moderate baseline stroke severity (NIHSS median score 10+ 6) were associated with major neurological improvement after adjusting for co variables. Major neurological improvement at 24 h was an independent predictor of good outcome (mRS=1) at 12 months (OR 13.9, 95% CI 6.84 to 40.2).
Age <60 years, glucose levels <8 mmol/L and mild to moderate stroke severity (NIHSS median score 10+/-6) was associated with major neurological improvement after intravenous rt-PA. Major neurological improvement at 24 h after the administration of intravenous thrombolysis independently predicted good outcome at 12 months.
尽管重组组织型纤溶酶原激活剂(rt-PA)在急性缺血性脑卒中的应用越来越多,但溶栓患者的短期和长期预后仍存在不确定性。
确定接受静脉 rt-PA 治疗的急性缺血性脑卒中患者在 24 小时时出现主要神经功能改善的预测因素,并分析其与 12 个月时的结局的关系。
我们分析了 2000 年 1 月至 2009 年 6 月在印度南部一家三级护理中心接受静脉 rt-PA 治疗的符合国立神经病学与卒中研究院(NINDS)标准的急性缺血性脑卒中患者的数据。主要神经功能改善定义为 NIHSS 评分增加 8 分或 24 小时时 NIHSS 评分为 0 或 1。良好结局定义为 12 个月时改良 Rankin 量表(mRS)评分为 0 至 1。
在接受静脉 rt-PA 治疗的 72 例急性缺血性脑卒中患者中,23 例(32%)患者在 24 小时时出现主要神经功能改善。年龄<60 岁(OR 1.9,95%CI 1.7 至 3.2)、入院时血糖水平<8mmol/L(OR 3.87,95%CI 1.9 至 9.2)和基线时轻度至中度脑卒中严重程度(NIHSS 中位数评分 10+6)与调整协变量后的 24 小时时主要神经功能改善相关。24 小时时的主要神经功能改善是 12 个月时良好结局(mRS=1)的独立预测因素(OR 13.9,95%CI 6.84 至 40.2)。
年龄<60 岁、血糖水平<8mmol/L 和轻度至中度脑卒中严重程度(NIHSS 中位数评分 10+/-6)与静脉 rt-PA 治疗后出现主要神经功能改善相关。静脉溶栓后 24 小时时的主要神经功能改善独立预测 12 个月时的良好结局。